GlaxoSmithKline Plc, which licenses the flu drug Relenza from Biota Holdings Ltd, paid the Australian company A$20 million (US$19.5 million) to settle a lawsuit.
Biota agreed to the payment, which is less than its legal costs, after the trial was postponed in May and lawyers said the delay would lead to increased costs and risks, the Melbourne-based company said yesterday in a statement.
“Our expectations were somewhere between A$50 million and A$100 million,” Scott Power, healthcare analyst at ABN Amro Morgans Ltd in Brisbane, said in a telephone interview yesterday. “Does that make this a bad outcome? No. It has removed uncertainty. They can now re-direct funds earmarked for legal costs to the development of their clinical program.”
Biota was seeking as much as A$704 million in lost income, saying Europe’s largest drugmaker had failed to adequately promote Relenza, also known as zanamivir. Royalties from the drug, which is the main competitor for Roche Holding AG’s Tamiflu, accounted for more than 70 percent of Biota’s A$56 million in sales last year.
Biota shares declined A$0.25, or 3.2 percent, to A$0.755, giving the company a market value of A$136.8 million. The stock has slumped almost 60 percent in the past year.
The company has incurred at least A$23.4 million in legal costs so far, based on its statements. Pursuing the case may have cost it A$20 million more, Power said.
He doesn’t own the shares, which he rates a “buy” and expects to reach A$1.26 within 12 months.
“We are pleased to have reached a settlement that is satisfactory for both companies and brings an end to this litigation,” Glaxo chief executive officer Andrew Witty said in yesterday’s statement.
The payment will be made on Aug. 18 and both companies will cover their own legal costs, Biota said.
“The focus will be on developing the Relenza franchise, particularly in the important market of pre-pandemic influenza risk management, an area of considerable concern to both governments and business,” Biota said in the statement.
WEAKER ACTIVITY: The sharpest deterioration was seen in the electronics and optical components sector, with the production index falling 13.2 points to 44.5 Taiwan’s manufacturing sector last month contracted for a second consecutive month, with the purchasing managers’ index (PMI) slipping to 48, reflecting ongoing caution over trade uncertainties, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The decline reflects growing caution among companies amid uncertainty surrounding US tariffs, semiconductor duties and automotive import levies, and it is also likely linked to fading front-loading activity, CIER president Lien Hsien-ming (連賢明) said. “Some clients have started shifting orders to Southeast Asian countries where tariff regimes are already clear,” Lien told a news conference. Firms across the supply chain are also lowering stock levels to mitigate
Six Taiwanese companies, including contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), made the 2025 Fortune Global 500 list of the world’s largest firms by revenue. In a report published by New York-based Fortune magazine on Tuesday, Hon Hai Precision Industry Co (鴻海精密), also known as Foxconn Technology Group (富士康科技集團), ranked highest among Taiwanese firms, placing 28th with revenue of US$213.69 billion. Up 60 spots from last year, TSMC rose to No. 126 with US$90.16 billion in revenue, followed by Quanta Computer Inc (廣達) at 348th, Pegatron Corp (和碩) at 461st, CPC Corp, Taiwan (台灣中油) at 494th and Wistron Corp (緯創) at
NEGOTIATIONS: Semiconductors play an outsized role in Taiwan’s industrial and economic development and are a major driver of the Taiwan-US trade imbalance With US President Donald Trump threatening to impose tariffs on semiconductors, Taiwan is expected to face a significant challenge, as information and communications technology (ICT) products account for more than 70 percent of its exports to the US, Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) president Lien Hsien-ming (連賢明) said on Friday. Compared with other countries, semiconductors play a disproportionately large role in Taiwan’s industrial and economic development, Lien said. As the sixth-largest contributor to the US trade deficit, Taiwan recorded a US$73.9 billion trade surplus with the US last year — up from US$47.8 billion in 2023 — driven by strong
ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip assembly and testing service provider, yesterday said it would boost equipment capital expenditure by up to 16 percent for this year to cope with strong customer demand for artificial intelligence (AI) applications. Aside from AI, a growing demand for semiconductors used in the automotive and industrial sectors is to drive ASE’s capacity next year, the Kaohsiung-based company said. “We do see the disparity between AI and other general sectors, and that pretty much aligns the scenario in the first half of this year,” ASE chief operating officer Tien Wu (吳田玉) told an
RSS